Korro Bio, Inc. (KRRO)

Market Cap	306.67M
Revenue (ttm)	n/a
Net Income (ttm)	-85.30M
Shares Out	9.30M
EPS (ttm)	-15.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	53,149
Open	32.83
Previous Close	33.00
Day's Range	32.02 - 33.31
52-Week Range	9.15 - 97.91
Beta	n/a
Analysts	Strong Buy
Price Target	123.75 (+275.23%)
Earnings Date	Nov 27, 2024

About KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 3, 2019
• Employees: 102
• Stock Exchange: NASDAQ
• Ticker Symbol: KRRO
• Website: https://www.korrobio.com

Analyst Forecast

According to 5 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price forecast is $123.75, which is an increase of 275.23% from the latest price.

Price Target

$123.75

(275.23% upside)

Analyst Consensus: Strong Buy